Abstract IA6: Identification and characterization of factors required for KRAS-driven pancreatic tumorigenesis

作者
Brian C. Lewis
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:75 (13_Supplement): IA6-IA6
标识
DOI:10.1158/1538-7445.panca2014-ia6
摘要

Abstract Activating mutations in the KRAS oncogene occur in the vast majority of pancreatic ductal adenocarcinomas (PDAC). These mutations are present in early precursor pancreatic intra-epithelial neoplasia (PanIN) lesions and are considered initiating driver mutations in this disease. Moreover, expression of an activated Kras allele potently initiates PanIN formation and PDAC development in the mouse. Therefore, inhibiting mutant KRAS-mediated signaling is potentially an effective therapeutic strategy for PDAC. While efforts directly targeting mutant KRAS are underway, an alternative approach is to target key signaling molecules that are stimulated downstream by activated KRAS. We hypothesized that factors required for the development of KRAS-driven pancreatic tumors will be similarly required during late stage disease and therefore represent potential therapeutic targets. We therefore utilize in vivo and in vitro systems to identify and characterize these factors. Mutated KRAS promotes the proliferation of primary pancreatic ductal epithelial cells (PDECs) as well as their survival following challenge with apoptotic stimuli. KRAS-induced survival in PDECs is dependent on signaling through the RAF/MEK/ERK and PI3K/AKT signaling cascades. Interestingly, we found that the insulin-like growth factor receptor (IGF1R) is required for KRASG12D-induced stimulation of the PI3K/AKT signaling axis. We determined that KRASG12D induces the expression of the IGF1R ligand IGF2 downstream of the MEK/ERK cascade and IGF2 stimulates IGF1R, and subsequently PI3K/AKT signaling, in an autocrine manner. Consistent with this, ectopic IGF2 expression restored KRASG12D-induced survival in cells treated with a MEK inhibitor but not a PI3K inhibitor. Critically, IGF1R is required for KRASG12D-induced survival after exposure to apoptotic stimuli, and inhibition of IGF1R impairs pancreatic tumor formation in an orthotopic mouse model. In PDAC cell lines, shRNA-mediated knockdown of IGF1R impairs their anchorage-independent growth and migration activity. Thus, IGF1R-mediated signaling is required for KRASG12D-driven pancreatic tumorigenesis in vivo and impacts the transformation of pancreatic cancer cells in culture. The mTOR signaling complex TORC2 promotes the phosphorylation of AKT on Ser473, an event required for full activation of AKT. Given the importance of IGF1R and PI3K/AKT signaling in promoting KRASG12D-induced survival and pancreatic tumor formation, we explored the requirement for TORC2 activity in KRAS-driven PDAC development in vivo. We inactivated TORC2 through the pancreas-specific genetic ablation of the essential subunit Rictor. Rictor deficient pancreata are architecturally normal but smaller than wild-type pancreata. Interestingly, Rictor deletion significantly impaired KRASG12D-driven PanIN formation. Moreover, the absence of Rictor also impaired KRASG12D-driven PanIN formation following caerulein-induced pancreatic injury. Together, these data indicate an important role for TORC2 signaling during PDAC initiation. We additionally characterized the role of TORC2 in PDAC cell lines. ShRNA-mediated inhibition of Rictor impaired PDAC cell proliferation and transformation as assessed by anchorage-independent growth, suggesting an important role for the TORC2 signaling complex in maintenance of the transformed phenotype of PDAC cells. Analysis of TORC substrate proteins identified reduced phosphorylation and activation of AKT and SGK1, suggesting these downstream molecules as potential mediators of TORC2-dependent phenotypes in pancreatic tumorigenesis. Together, these data suggest that TORC2 activity plays a critical role in KRAS-driven PDAC initiation and progression. Collectively, our studies have identified critical factors required for KRAS-driven pancreatic tumorigenesis, suggesting additional therapeutic strategies for targeting PDAC. Citation Format: Brian C. Lewis. Identification and characterization of factors required for KRAS-driven pancreatic tumorigenesis. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr IA6.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
徐华佳发布了新的文献求助10
1秒前
徐睿完成签到,获得积分10
1秒前
1秒前
1秒前
molihuakai的应助被Kathy采纳,获得10
1秒前
酷波er的应助被暴龙战士采纳,获得10
2秒前
4秒前
文静念真发布了新的文献求助10
4秒前
两脚兽大人完成签到 ,获得积分10
4秒前
困困完成签到 ,获得积分10
5秒前
5秒前
6秒前
vamcello发布了新的文献求助10
6秒前
莓莓发布了新的文献求助10
7秒前
单薄雪巧完成签到 ,获得积分10
8秒前
8秒前
科研小白发布了新的文献求助10
8秒前
9秒前
9秒前
Tracy完成签到,获得积分10
10秒前
小艾同学发布了新的文献求助10
11秒前
吴剑锋完成签到 ,获得积分10
11秒前
水煮电吹风的应助被pp采纳,获得10
11秒前
11秒前
Luxury完成签到 ,获得积分10
11秒前
oo完成签到,获得积分10
13秒前
徐华佳完成签到,获得积分20
13秒前
哈哈哈完成签到,获得积分20
13秒前
糟糕的烤鸡完成签到,获得积分10
13秒前
cheng完成签到,获得积分20
15秒前
浅唱夏末完成签到,获得积分10
15秒前
17秒前
JamesPei的应助被叁叁采纳,获得10
17秒前
Ren发布了新的文献求助20
17秒前
Estella完成签到,获得积分10
19秒前
科研小白完成签到,获得积分20
20秒前
金山完成签到,获得积分10
20秒前
20秒前
21秒前
o仔完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552